candesartan has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bivalacqua, TJ; Champion, HC; Kadowitz, PJ; Lambert, DG; McNamara, DB | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L | 1 |
| Brosnihan, KB; Diz, DI; Ferrario, CM; Fukuhara, M; Li, P; Neves, LA | 1 |
| Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L | 1 |
| Alhenc-Gelas, F; Bergaya, S; Bloch-Faure, M; Boulanger, CM; Dong, Y; Hilgers, RH; Inagami, T; Lévy, BI; Meneton, P | 1 |
| Andoh, Y; Dong, J; Fujii, S; Furumoto, T; Imagawa, S; Ishimori, N; Ohmura, K; Ohmura, Y; Sato, Y; Tsutsui, H | 1 |
1 review(s) available for candesartan and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Disease; Coronary Thrombosis; Humans; Losartan; P-Selectin; Platelet Activation; Platelet Aggregation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Thromboxane; Tetrazoles; Thrombosis; Thromboxane A2; Valine; Valsartan | 2001 |
1 trial(s) available for candesartan and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Female; Humans; Hypertension; Light; Losartan; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Scattering, Radiation; Tetrazoles; Therapeutic Equivalency | 2007 |
5 other study(ies) available for candesartan and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
| Article | Year |
|---|---|
The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calcium Channel Agonists; Dose-Response Relationship, Drug; Female; Hemodynamics; Hindlimb; Imidazoles; Injections, Intravenous; Male; Norepinephrine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Vasoconstrictor Agents | 1999 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan | 2001 |
The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Dose-Response Relationship, Drug; Hindlimb; Irbesartan; Male; Phenylephrine; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Thromboxane; Tetrazoles; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2001 |
Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bradykinin; Bradykinin B2 Receptor Antagonists; Carotid Arteries; Hemorheology; Imidazoles; Losartan; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenylephrine; Pyridines; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Tissue Kallikreins; Vasodilation; Vasodilator Agents | 2004 |